MS drug shows promise for preventing heart failure

A drug already approved to treat multiple sclerosis may also hold promise for treating cardiac hypertrophy, or thickening of the cardiac muscle - a disorder that often leads to heart failure, researchers at the University of Illinois at Chicago College of Medicine report. The findings are published in the July 16 issue of Circulation: Heart Failure. Cardiac hypertrophy is a slow thickening of the heart muscle that shrinks the interior volume of the heart, forcing the organ to work harder to pump a diminishing volume of blood. "There comes a day when the heart just can't keep up any more, and it fails," says R. John Solaro, UIC distinguished university professor and head of physiology and biophysics. Cardiac hypertrophy, which afflicts one in 500 people, can be caused by high blood pressure or inherited through genes that control contraction of the heart. Solaro and his colleagues believe that if the thickening of the heart muscle could be slowed, or maybe even reversed, heart failure could be prevented